PKSI-527
PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system[1].
Product Specifications
CAS Number
128837-71-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Kallikrein
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pksi-527.html
Concentration
10mM
Purity
95.39
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC[C@@H]1CC[C@H](CC1)C(N[C@H](C(NC2=CC=C(C=C2)CC(O)=O)=O)CC3=CC=CC=C3)=O.Cl
Molecular Formula
C25H32ClN3O4
Molecular Weight
473.99
Precautions
H302, H315, H319
References & Citations
[1]Fujimori Y, et al. Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice. Agents Actions. 1993 May;39 (1-2) :42-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
